| Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial |
65 |
| ARISE: A Phase 3 randomized trial of erenumab for episodic migraine |
56 |
| CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications |
35 |
| Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults |
33 |
| Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition Asbtracts |
27 |
| CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice |
22 |
| Development of CGRP-dependent pain and headache related behaviours in a rat model of concussion: Implications for mechanisms of post-traumatic headache |
22 |
| Perceived triggers of primary headache disorders: A meta-analysis |
21 |
| Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study |
21 |
| Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial |
20 |
| Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition |
20 |
| Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial |
20 |
| A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study) |
18 |
| Recognizing the role of CGRP and CGRP receptors in migraine and its treatment |
18 |
| Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study |
17 |
| Peripheral and central nervous system distribution of the CGRP neutralizing antibody [I-125] galcanezumab in male rats |
16 |
| Distribution of CGRP and CGRP receptor components in the rat brain |
16 |
| A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody |
15 |
| Static and dynamic functional connectivity differences between migraine and persistent post-traumatic headache: A resting-state magnetic resonance imaging study |
15 |
| Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine |
14 |
| Assessing the impact of headaches and the outcomes of treatment: A systematic review of patient-reported outcome measures (PROMs) |
14 |
| Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study |
13 |
| Hypothalamic regulation of headache and migraine |
13 |
| CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data |
13 |
| Calcitonin-gene related peptide and disease activity in cluster headache |
13 |
| Headache, comorbidities and lifestyle in an adolescent population (The TEENs Study) |
12 |
| Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults |
12 |
| Current understanding of meningeal and cerebral vascular function underlying migraine headache |
12 |
| Musculoskeletal dysfunction in migraine patients |
12 |
| A randomized trial of telemedicine for migraine management |
12 |
| Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine |
12 |
| Topiramate is more effective than acetazolamide at lowering intracranial pressure |
12 |
| Vagus nerve stimulation for primary headache disorders: An anatomical review to explain a clinical phenomenon |
12 |
| Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN |
11 |
| Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure |
10 |
| Current understanding of trigeminal ganglion structure and function in headache |
10 |
| Current understanding of thalamic structure and function in migraine |
10 |
| RNA-Seq investigations of human post-mortem trigeminal ganglia |
10 |
| Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial |
10 |
| Recurrent administration of the nitric oxide donor, isosorbide dinitrate, induces a persistent cephalic cutaneous hypersensitivity: A model for migraine progression |
10 |
| CGRP receptor antagonist MK-8825 attenuates cortical spreading depression induced pain behavior |
10 |
| Molecular studies of CGRP and the CGRP family of peptides in the central nervous system |
10 |
| When migraine mimics stroke: A systematic review |
10 |
| Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study) |
10 |
| Gender aspects of CGRP in migraine |
10 |
| Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives |
10 |
| The effects of aerobic exercise for persons with migraine and co-existing tension-type headache and neck pain. A randomized, controlled, clinical trial |
10 |
| Lifestyle factors and risk of migraine and tension-type headache. Follow-up data from the Nord-Trondelag Health Surveys 1995-1997 and 2006-2008 |
9 |
| A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects |
9 |
| Correlation between nerve atrophy, brain grey matter volume and pain severity in patients with primary trigeminal neuralgia |
9 |
